Mobile Observation Of Depression (MOOD) platform for digital phenotyping

总部设在苏塞克斯创新中心的EMTEQ有限公司正在开发一种可穿戴的数字平台，可以实时客观地监测新的抑郁症标志物。世界卫生组织(WHO)估计，目前有超过3亿人患有抑郁症。在英国，多达10%的人会在一生中的某个时候患有抑郁症；每年开出的抗抑郁药处方超过5700万张(英格兰，2014年)。世界范围内抑郁症发病率的上升归因于压力的增加和生活方式的改变。治疗抑郁症患者的经济成本为2085 GB/人/年，生产力损失每年占75亿GB。大多数精确医学方法寻找遗传或分子疾病标记。然而，尽管囊性纤维化等一些疾病具有强大的遗传影响，但双胞胎研究表明，对于可预防死亡的前十大原因，基因只起到了很小的预测作用。导致早逝的前十大原因都有很强的行为影响，因此基于数字表型的预测性分析在挽救生命方面具有巨大的潜力。目前，临床医生还没有技术来客观测量重度抑郁症患者的情绪反应。在临床实践中，对症状和体征的评估和记录依赖于患者的主观回忆和对他们当天感觉的“快照”。在这方面，日常活动中的客观监测系统可能会对治疗分层和遵从性以及了解快乐的个人驱动因素产生巨大影响。我们正在与领先的精神健康专家(MindTech、苏塞克斯伙伴NHS信托基金)合作，开发用于患者诊断、分层和治疗监测的“情绪”平台。苏塞克斯伙伴NHS信托基金在260多个地点运营，包括社区服务，服务人口155万人。MindTech在确保足够的公共患者代表性、用户界面设计和临床路径建议方面发挥了重要作用。我们已投入巨资建立一个由商业和学术合作伙伴组成的国际网络。成功的项目交付将巩固我们作为业内领先创新者的声誉，是颠覆抑郁症治疗和筛查市场的雄心勃勃的商业战略的第一步。“

"Emteq Ltd, based at the Sussex Innovation Centre, is developing a wearable digital platform that allows real-time objective monitoring of novel markers of depression.The World Health Organization (WHO) estimates more than 300m people are living with depression. In the UK, up to 10% of people will suffer from depression at some point in their lives; accounting for over 57m annual antidepressant prescriptions (England, 2014). The rising incidence of depression worldwide is attributed to increased stress and changing lifestyle. The economic cost of treating a patient with depression is £2,085/person/year and productivity losses account for £7.5b annually.Most precision medicine approaches look for genetic or molecular disease markers. However, whilst some conditions such as cystic fibrosis have and strong genetic influence, twin studies show that for the top ten causes of preventable deaths, genes contribute only a minor predictive role. All of the top ten causes of premature death have a strong behavioural influence, therefore predictive analytics based on digital phenotyping has huge potential to save lives.Currently, no technology is available for clinicians to measure emotional responses objectively in people with major depression. In clinical practice, assessment and documentation of symptoms and signs relies on the patients' subjective recall and a 'snapshot' of how they are feeling on the day. In this respect, a system for objective monitoring during day-to-day activities could have a tremendous impact on treatment stratification and compliance, and understanding individual drivers of happiness.We are collaborating with leading specialists in mental health (MindTech, Sussex Partnership NHS Trust), to develop the 'MOOD' platform for use in patient diagnosis, stratification and treatment monitoring.Sussex Partnership NHS Trust operates from over 260 sites, including community services, and serves a population of 1.55 million people. MindTech is instrumental in ensuring adequate Public Patient Representation, user interface design and advice on clinical pathways.We have invested heavily in building an international network of commercial and academic partners. Successful project delivery will cement our reputation as leading innovators within the industry and is the first step in an ambitious commercial strategy to disrupt the depression treatment and screening markets."